General MedicationsORALStandard
PROGRAF
TACROLIMUS
Standard Dose
EQ 0.2MG BASE/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview PROGRAF is listed in Drugs@FDA under application 210115 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TACROLIMUS Form and strength FOR SUSPENSION;ORAL - EQ 0.2MG BASE/PACKET Sponsor ASTELLAS Submission history Latest submission status date: 2023-09-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview PROGRAF is listed in Drugs@FDA under application 210115 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TACROLIMUS Form and strength FOR SUSPENSION;ORAL - EQ 0.2MG BASE/PACKET Sponsor ASTELLAS Submission history Latest submission status date: 2023-09-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.